: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science
1985, 230:1132–1139.PubMedCrossRef 6. Popescu NC, King CR, Kraus MH: Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12–21.32. Genomics 1989, 4:362–366.PubMedCrossRef 7. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2:127–137.PubMedCrossRef 8. Slamon DJ, Godolphin W, Jones LA: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707–712.PubMedCrossRef 9. Verri E, Guglielmini P, Puntoni M: HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Oncology 2005, 68:154–161.PubMedCrossRef 10. Cheng JD, Rieger PT, von Mehren M: Recent advances in immunotherapy and monoclonal antibody treatment of cancer. Semin Oncol Nurs 2000, 16:2–12.PubMedCrossRef 11. learn more Bell Richard: What Can We Learn from Herceptin Trials in Metastatic Breast Cancer? Oncology 2002, 63:39–46.PubMedCrossRef 12. Cuello Mauricio, Seth A, Ettenberg , Amy S, et al.: Down-Regulation of the erbB-2 Receptor by Trastuzumab (Herceptin) Enhances Tumor Necrosis Factor-related
Apoptosis-inducing Ligand-mediated Apoptosis in Breast and Ovarian Cancer Cell Lines that Overexpress erbB-2. Cancer Res 2001, 61:4892–900.PubMed 13. Cho HS, Mason K, Ramyar KX, et al.: Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. SYN-117 clinical trial Nature 2003, 421:756–760.PubMedCrossRef 14. Fujimura M, Katsumata N, Tsuda H, et al.: HER2 Is Frequently Acalabrutinib Over-expressed in Ovarian Clear Cell Adenocarcinoma: Possible Novel Treatment Modality Using Recombinant Monoclonal Antibody against HER2, Trastuzumab. Jpn J Cancer Res 2002,
93:1250–1257.PubMed 15. Dean-Colomb W, Esteva FJ: Her2-positive breast cancer: herceptin and beyond. Eur J Cancer 2008, 44:2806–2812.PubMedCrossRef 16. Cheng LS, Liu AP, Yang JH: Construction, expression and characterization of the engineered PRKACG antibody against tumor surface antigen, p185(c-erbB-2). Cell Res 2003, 13:35–48.PubMedCrossRef 17. Wang Jing, Shi Yu, Liu Yanqi: Purification and characterization of a single-chain chimeric anti-p185 antibody expressed by CHO-GS system. Protein expression and purification 2005, 41:68–76.PubMedCrossRef 18. Hu S, Zhu Z, Li L, et al.: Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism. Proteins 2008, 70:938–949.PubMedCrossRef 19. Wang C, Li Y, Li P: Generation and Characterization of monoclonal antibodies specific for the oncogene product P185 neu/c-erbB-2 by surface epitope masking (SEM). J Chin Immunol 2000, 16:539–541. 20. Ping LI, Yun LI, Chen Wang: Investigation on the anti-cancer activities of anti-p185 monoclonal antibodies in vitro. Chin Immunol 2002, 18:33–35. 21. Steffen AC, Göstring L, Tolmachev V, et al.